Analysts Set Target Price of $10.90 for TriSalus Life Sciences

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have received a consensus rating of “Buy” from eight research firms monitoring the stock, according to MarketBeat Ratings. While one analyst has assigned a sell rating, five have recommended a buy, and two have opted for a strong buy. The average target price set by analysts for the next year is $10.90.

Recent evaluations by various firms have highlighted differing perspectives on the company’s performance. For instance, Weiss Ratings reiterated a “sell (d-)” rating on October 8, 2023. Additionally, Wall Street Zen downgraded TriSalus Life Sciences from a “hold” to a “sell” rating in a report published on September 28, 2023.

Current Stock Performance and Earnings Report

On October 11, 2023, shares of TLSI opened at $5.02. The company boasts a market capitalization of $250.33 million, with a price-to-earnings ratio standing at -4.25 and a beta of 0.47. The stock has shown fluctuations over the past year, reaching a low of $3.42 and a high of $5.88.

TriSalus Life Sciences recently announced its earnings results for the quarter ended August 12, 2023. The company reported earnings per share (EPS) of ($0.27), which was below the consensus estimate of ($0.22), missing expectations by $0.05. Revenue for the quarter totaled $11.21 million, exceeding the consensus estimate of $10.69 million. Analysts project that TriSalus will report an EPS of -1.55 for the current fiscal year.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc. is a medical technology company focused on developing innovative drug delivery technologies and immune-oncology therapeutics specifically for treating liver and pancreatic cancers. Its offerings include the Pressure Enabled Drug Delivery systems, such as the TriNav infusion system, utilized for transarterial radioembolization and chemoembolization procedures targeting liver cancer and metastases. Furthermore, the company is currently conducting a Phase 1 clinical trial for its Pancreatic Retrograde Venous Infusion device, designed for patients with locally advanced pancreatic cancer.

As the market continues to assess TriSalus Life Sciences’ potential, the mixed ratings from analysts reflect a broader conversation about the company’s future in the competitive landscape of medical technology.